Hosted on MSN1y
Beam Rockets 26%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
That conditioning regimen can make a patient ... Both of these will be in vivo gene-editing drugs, Beam stock analyst Sami Corwin, of William Blair, said in a report. Financially, Leerink Partners ...
Hosted on MSN2mon
Beam presents new NHP data demonstrating proof-of-concept for ESCAPE
ESCAPE is comprised of two investigational drug products ... to traditional transplant myeloablative conditioning. The company intends to advance BEAM-103 and BEAM-104 for development in sickle ...
pharmaphorum1y
Lilly buys Beam’s option on Verve drug programmes
The biotech has decided to focus its efforts on certain drug candidates like BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency and offer others up for ...